Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 2002

View Archived Issues

Schering-Plough presents 2001 annual report

Potent inhibitors of angiogenesis derived from thrombospondin-1

Cephalon designs new inhibitors of VEGF-dependent angiogenesis with good oral antitumor activity

Preliminary phase I results for ILX-651 discussed at AACR meeting

Preclinical characterization of Ro-31-7453, a new cell cycle inhibitor

SAR leading to TBC-3711, a potent, orally active, ETA-selective endothelin antagonist

Enrollment completed in phase II/III trial of Neurodex for emotional lability

Novartis presents data on the balanced NK1/NK2 antagonist DNK-333

Phase IB safety study of Moli-1901 in cystic fibrosis yields favorable results

Health Canada approves phase I/II Reolysin trial in patients with recurrent malignant glioma

ChemGenex uses chemical genomics to advance experimental anticancer drugs

Affitech acquires exclusive worldwide license for Troybodies technology

GW expands phase III program for cannabis-based medicines

Phase I/II results for WX-G250 in metastatic RCC indicate clinical benefit and good tolerance

Alliance for research on interferon gamma-1b for asthma

HE-2200 for potentiating impaired immune systems

Inhibitors of Src tyrosine kinases reported by AstraZeneca

Pharmacodynamic and pharmacokinetic effects of renzapride examined in IBS

Collaboration to identify single-chain antibody therapeutics

FDA concerns will delay Ariza marketing

Calcium receptor antagonists especially useful in osteoporosis according to JT

Agouron designs new series with protein kinase-inhibitory and antitumor activity

Roche patents prodrugs of NMDA receptor antagonists

New MC4-selective agonists useful in obesity, etc.

Patent covers Genentech's new alpha4 integrin receptor ligands

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...